Results 151 to 160 of about 43,753 (252)

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. [PDF]

Front Oncol, 2022
Luo J, Ou S, Wei H, Qin X, Jiang Q.
europepmc   +1 more source

Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Regulated cell death pathways, including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy‐dependent cell death, interact with mitochondrial dysfunction, proteostasis failure, lysosomal stress, glial remodeling, and neuroinflammation across major neurodegenerative diseases.
Tianjiao Li, Qian Zhang, Yichen Wu, Ruixue Huang   +3 more
wiley   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol, 2022
Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B.   +5 more
europepmc   +1 more source

Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances

MedComm, Volume 7, Issue 9, September 2026.
The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong, Moran Chen, Xupeng Hou, Xiaoya Tang, Xiaoli Yu, Jing Liu   +5 more
wiley   +1 more source

Therapy-related myeloid neoplasms in Korean patients with ovarian or primary peritoneal cancer treated with poly(ADP-ribose) polymerase inhibitors. [PDF]

Transl Cancer Res
Jang YJ, Kim H, Ryu SY, Kim MH, Kim BJ, Jung HJ, Kang J, Yang SH, Na II, Lee HR, Kang HJ.   +10 more
europepmc   +1 more source

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data. [PDF]

Front Pharmacol, 2022
Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, Yang Y.   +6 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature. [PDF]

Case Rep Oncol
Koheeallee K, Sarivalasis A.
europepmc   +1 more source

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency Signature. [PDF]

JCO Precis Oncol, 2023
Batalini F, Madison RW, Sokol ES, Jin DX, Chen KT, Decker B, Pavlick DC, Frampton GM, Wulf GM, Garber JE, Oxnard G, Schrock AB, Tung NM.   +12 more
europepmc   +1 more source